期刊
COORDINATION CHEMISTRY REVIEWS
卷 257, 期 11-12, 页码 1764-1776出版社
ELSEVIER SCIENCE SA
DOI: 10.1016/j.ccr.2013.01.034
关键词
Iridium; Rhodium; Anti-cancer; Metallodrug; Inorganic medicine
资金
- Hong Kong Baptist University [FRG2/11-12/009]
- Center for Cancer and Inflammation Research, School of Chinese Medicine (CCIR-SCM, HKBU)
- Health and Medical Research Fund [HMRF/11101212]
- Research Grants Council [HKBU/201811, HKBU/204612]
- French National Research Agency/Research Grants Council [A-HKBU201/12]
- Science and Technology Development Fund, Macao SAR [001/2012/A]
- University of Macau [MYRG091(Y2-L2)-ICMS12-LCH, MYRG121(Y2-L2)-ICMS12-LCH]
Group 9 metal complexes based on iridium and rhodium have recently arisen as fascinating potential alternatives to existing platinum and ruthenium metallodrugs. While long regarded as chemically inert, studies over the past few years have demonstrated that the reactivity and biological activity of iridium and rhodium complexes may be unlocked by a suitable choice of auxiliary ligands. In addition, group 9 metal centers have received increased popularity for the construction of kinetically inert organometallic scaffolds as target-selective protein or enzyme inhibitors. In this review, we summarize the recent strategies that have been utilized for the design and development of bioactive iridium and rhodium complexes. (C) 2013 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据